Disc Medicine IRON Business Segments
| FY'25 | FY'24 | ||
|---|---|---|---|
| Research And Development Expense by Product | |||
| Bitopertin | $58.83M+109% | $28.11M+62.7% | |
| DISC Three Four Zero Five | $17.69M+27.0% | $13.93M-30.9% | |
| DISC Zero Nine Seven Four | $27.59M+62.8% | $16.94M+85.5% | |
| Internal Research And Development | $36.95M+55.4% | $23.78M+47.1% | |
| Other Research | $13.6M+97.7% | $6.88M+44.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Disc Medicine break its business down?
- Disc Medicine (IRON) reports research and development expense by product across 5 parts — Bitopertin, DISC Three Four Zero Five, DISC Zero Nine Seven Four, Internal Research And Development and Other Research. Each is extracted from the segment footnotes and tracked over time.
- Where does Disc Medicine's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Disc Medicine's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.